Symptomatic treatment of chronic idiopathic urticaria.
Composition:
1 tabl powl. contains 180 mg of fexofenadine hydrochloride (equivalent to 168 mg of fexofenadine).
Action:
An antihistamine blocking H-receptors1, not exerting a sedative effect. Fexofenadine is the pharmacologically active metabolite of terfenadine. It does not sedate or cause significant QT interval changesc in the ECG picture. It is quickly absorbed from the digestive tract. Tmax is achieved after about 1-3 h after administration. Fexofenadine binds in 60-70% with plasma proteins and is minimally metabolised (in the liver and out of the liver). T0,5 in the final phase of elimination is 11-15 h after repeated administration. It is excreted primarily from the bile, up to 10% of the dose is excreted in the urine in unchanged form.
Contraindications:
Hypersensitivity to the components of the preparation.
Precautions:
Particularly cautiously use in elderly patients and patients with impaired renal or hepatic function. Caution should be exercised in patients with a current or previous history of cardiovascular disease (risk of tachycardia or palpitations). There are no data on safety and efficacy in children under 12 years of age.
Pregnancy and lactation:
Do not use during pregnancy unless clearly necessary. Use during breastfeeding is not recommended.
Side effects:
Common: headaches, drowsiness, dizziness, nausea. Uncommon: fatigue. Not known: hypersensitivity reactions (angioneurotic edema, tightness in the chest, shortness of breath, skin redness and generalized anaphylaxis), insomnia, nervousness, sleep disturbances or nightmares / expressive dreams, tachycardia, palpitations, diarrhea, rash, urticaria, itching.
Dosage:
Orally. Adults and children over the age of 12: 1 tabl. once a day, before a meal.
(C)
